scholarly journals Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Lan Li ◽  
Chaohui Yu
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Precancerous Lesions ◽  
Cost Effective ◽  
Reduce Healthcare Cost ◽  
Metachronous Gastric Cancer ◽  
H Pylori ◽  
Meta Analyses

The role of Helicobacter pylori (H. pylori) infection in patients following endoscopic resection of early gastric cancer (EGC) remains unclear. This article presents a review of literature published in the past 15 years. H. pylori‐mediated persistent methylation levels are associated with the development of metachronous gastric cancer. The methylation of certain specific genes can be used to identify patients with a high risk of metachronous gastric cancer even after H. pylori eradication. H. pylori eradication after endoscopic resection should be performed as early as possible for eradication success and prevention of metachronous precancerous lesions. Although whether the eradication of H. pylori could prevent the development of metachronous cancer after endoscopic resection is controversial, several meta‐analyses concluded that H. pylori eradication could reduce the incidence of metachronous gastric cancer significantly. In addition, H. pylori eradication in gastric cancer survivors after endoscopic resection could reduce healthcare cost and save lives in a cost‐effective way. Taken together, H. pylori eradication after endoscopic resection of EGC is recommended as prevention for metachronous precancerous lesions and metachronous gastric cancer.

H. Pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection of early gastric cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A744
Author(s):  
Mototsugu Kato ◽  
Kaku Hokari ◽  
Jun Ishizuka ◽  
Takuji Mizushima ◽  
Yoshito Komatsu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Metachronous Gastric Cancer ◽  
H Pylori

H. Pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection of early gastric cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A744-A744
Author(s):  
M KATO ◽  
K HOKARI ◽  
J ISHIZUKA ◽  
T MIZUSHIMA ◽  
Y KOMATSU ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Metachronous Gastric Cancer ◽  
H Pylori

Sa1892 The Association Between Helicobacter pylori Status and Incidence of Metachronous Gastric Cancer After Endoscopic Resection of Early Gastric Cancer

2013 ◽  
Vol 144 (5) ◽  
pp. S-328-S-329 ◽  
Author(s):  
Young-Il Kim ◽  
Myeong-Cherl Kook ◽  
Hee-Won Kwak ◽  
Soo-Jeong Cho ◽  
Jong Yeul Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Metachronous Gastric Cancer

scholarly journals Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection

2021 ◽  
Vol 11 (1) ◽  
pp. 193
Author(s):  
Ji Eun Kim ◽  
Tae Jun Kim ◽  
Hyuk Lee ◽  
Yeong Chan Lee ◽  
Hwe Hoon Chung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Endoscopic Resection ◽  
Cumulative Incidence ◽  
Primary Outcome ◽  
Significant Difference ◽  
Metachronous Gastric Cancer ◽  
H Pylori ◽  
Anti Tumor Activity

Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important. The anti-tumor activity of aspirin has been demonstrated, but its efficacy in preventing MGC remains controversial. We evaluated the effect of aspirin on metachronous recurrence in H. pylori-negative patients. Methods: A total of 4351 patients were evaluated between January 2007 and December 2016, and 2151 patients who met the inclusion criteria were analyzed. The primary outcome was the cumulative incidence of MGC after an endoscopic resection for EGC. Results: During a 5-year median follow-up (interquartile range, 3.5–6.2), MGC developed in 176 (7.7%) patients, with a cumulative incidence of 89.4% in aspirin users and 92.7% in non-users; this difference was not statistically significant (p = 0.64). The duration of aspirin uses and the occurrence of MGC in both groups were not significantly different. There was no significant difference between groups when the duration of aspirin use was categorized into ≤1 year (hazard ratio (HR), 0.64; 0.20–2.01, p = 0.45), 1–4 years (HR, 1.35; 0.66–2.76, p = 0.41), and >4 years (HR, 1.17; 0.67–2.03, p = 0.58). Conclusions: Aspirin use was not associated with a lower risk of MGC in H. pylori-negative patients. Further prospective studies are needed.

Sign in / Sign up

Export Citation Format

Share Document